NJOY

A federal judge in Texas on Oct. 8 granted a joint request by the FDA and plaintiffs including Altria subsidiaries Helix Innovations and NJOY to stay litigation challenging the agency's 2021 PMTA rule. The court cited FDA's anticipated rulemaking concerning the regulation at issue. FDA announced on Sept. 28 that it intends to reassess the PMTA framework and could initiate new rulemaking to replace it. The parties must file a joint status report within 45 days and every 45 days thereafter. A motion by three Reynolds American companies to intervene remains pending.

Altria announces today its operating company NJOY has filed sweeping litigation against 34 foreign and domestic manufacturers, distributors and online retailers of illicit disposable products that are unlawfully marketed and sold in the State of California and elsewhere.

NJOY, a subsidiary of Ochiai, has filed a lawsuit accusing 34 manufacturers, distributors, and online retailers of illegally selling disposable e-cigarette products.

Altria's e-cigarette company, NJOY, has sued competitor Juul Labs, seeking to ban its import and sales of Juul products.

Altria's subsidiary NJOY has filed a patent infringement lawsuit against JUUL LAB, seeking to ban the import and sale of certain e-cigarette products.

JUUL has filed a 337 investigation request against NJOY, accusing it of patent infringement and seeking to ban its products in the US.

On June 30th, JUUL filed a complaint against NJOY for patent infringement with the ITC and an Arizona court.

Altria is set to acquire NJOY for $2.75 billion, gaining control of the largest e-cigarette category in the US.